natgillin/translations-raw huggingface dataset:
In chronic renal failure patients, correction for anaemia may lead to increased appetite, and potassium and protein intake.
Kod bolesnika s kroničnim zatajenjem bubrega, korekcija anemije može dovesti do povećanog apetita i unosa kalija i proteina.
In cirrhotic patients (non-smokers) with moderate hepatic impairment (classified as Child Pugh B), riociguat mean AUC was increased by 51% compared to healthy controls.
U bolesnika s cirozom (nepušača) i umjerenim oštećenjem funkcije jetre (klasificiranog kao Child-Pugh B), srednja vrijednost AUC riocigvata bila je povećana za 51% u usporedbi sa zdravim kontrolnim ispitanicima, što je unutar normalne intraindividalne varijabilnosti.
In CKD patients receiving dialysis who were administered Mimpara, approximately 30% of patients had at least one serum calcium value less than 7.5 mg/dl (1.9 mmol/l).
U bolesnika s kroničnom bolesti bubrega na dijalizi koji su liječeni Mimparom, otprilike 30% bolesnika imalo je najmanje jednu vrijednost serumskog kalcija manju od 7,5 mg/dl (1,9 mmol/l).
In CLARITY, there was an overall increase in bleeding in the clopidogrel + ASA group (17.4%) vs. the placebo + ASA group (12.9%).
U studiji CLARITY uočeno je ukupno povećanje krvarenja u grupi koja je primala klopidogrel uz ASK u odnosu na skupinu koja je uzimala placebo uz ASK.
In class III or IV PAH that was either primary or caused by scleroderma, the two studies showed that patients treated with Tracleer were able to walk further than patients treated with placebo after 16 weeks (44 metres further in the larger study), but there were too few patients with class IV disease to support the use of the medicine in this group.
Za stupanj III ili IV PAH-a koji je primaran ili uzrokovan sklerodermom, u dva ispitivanja utvrđeno je da su bolesnici liječeni lijekom Tracleer mogli hodati dalje od bolesnika liječenih placebom nakon 16 tjedana (44 metra dalje u većim ispitivanjima), no ispitivanjem je obuhvaćen premali broj bolesnika sa stupnjem IV bolesti da bi se podržala primjena lijeka u ovoj grupi.
In clincial trials ophthalmologic reactions, including uveitis, iridocyclitis and iritis, have been reported in patients treated with dabrafenib as monotherapy and in combination with trametinib.
U kliničkim ispitivanjima zabilježene su oftalmološke reakcije koje uključuju uveitis, iridociklitis i iritis u bolesnika liječenih dabrafenibom kao monoterapijom i u kombinaciji s trametinibom.
In clincial trials uveitis and iridocyclitis have also been reported in patients treated with trametinib in combination with dabrafenib.
U kliničkim ispitivanjima zabilježeni su i uveitis i iridociklitis u bolesnika liječenih trametinibom u kombinaciji s dabrafenibom.
In clinical controlled studies of efavirenz, nervous system symptoms of moderate to severe intensity were experienced by 19% (severe 2%) of patients, and 2% of patients discontinued therapy due to such symptoms.
U klinički kontroliranim ispitivanjima efavirenza simptomi živčanog sustava umjerenog do teškog intenziteta uočeni su u 19% (teški oblik 2%) pacijenata, a u 2% pacijenata terapija je zbog tih simptoma prekinuta.
In clinical COPD studies, approximately 16% of patients experienced adverse reactions with roflumilast (compared to 5% in placebo).
U kliničkim ispitivanjima kod bolesnika s KOPB-om, približno 16% bolesnika liječenih Daxasom imalo je nuspojave (u usporedbi s 5% na placebu).
In clinical drug-drug interaction studies in healthy subjects, delamanid was administered alone (100 mg twice daily) and with tenofovir (300 mg daily) or lopinavir/ritonavir (400/100 mg daily) for 14 days and with efavirenz for 10 days (600 mg daily).
U kliničkim ispitivanjima interakcija lijekova u zdravih ispitanika, delamanid je primijenjen sam (100 mg dvaput dnevno) i sa tenofovirom (300 mg dnevno) ili lopinavirom/ritonavirom (400/100 mg dnevno) tijekom 14 dana i sa efavirenzom tijekom 10 dana (600 mg dnevno).
In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or ciclosporin.
U kliničkim ispitivanjima interakcija amlodipin nije utjecao na farmakokinetiku atorvastatina, digoksina, varfarina ili ciklosporina.
In clinical interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of granisetron.
U kliničkim ispitivanjima interakcija, aprepitant nije imao klinički značajne učinke na farmakokinetiku granisetrona.
In clinical pharmacology studies, the half-life of naloxegol at therapeutic dose ranged from 6–11 hours.
U kliničkim farmakološkim ispitivanjima poluvijek naloksegola u terapijskim dozama kretao se u rasponu od 6-11 sati.
In clinical pharmacology trial WP18551, after a single dose intravenous administration of 6 mg (15 minutes infusion), mean AUC0-24 increased by 14% and 86%, respectively, in subjects with mild (mean estimated CLcr=68.1 mL/min) and moderate (mean estimated CLcr=41.2 mL/min) renal impairment compared to healthy volunteers (mean estimated CLcr=120 mL/min).
U kliničkom farmakološkom ispitivanju WP18551, nakon intravenske primjene jedne doze od 6 mg (15-minutna infuzija) prosječni AUC0-24 se povećao za 14% u ispitanika s blagim (srednja procijenjena vrijednost CLcr = 68,1 ml/min) odnosno za 86% u ispitanika s umjerenim (srednja procijenjena vrijednost CLcr = 41,2 ml/min) oštećenjem bubrega u usporedbi sa zdravim dobrovoljcima (srednja procijenjena vrijednost CLcr = 120 ml/min).
In clinical pharmacology trials in adults, co-administration with alcohol did not increase the alcohol- induced impairment in performance or increase in sleepiness.
U kliničkim farmakološkim ispitivanjima u odraslih, istovremena primjena desloratadina i alkohola nije pojačala štetne učinke alkohola na ponašanje ili povećala pospanost.
In clinical phase III, at total of 384 patients were treated with Ameluz.
U kliničkom ispitivanju faze III, ukupno je 384 bolesnika bilo liječeno lijekom Ameluz.
In clinical practice, treatment is usually continued until the infant has reached a post-menstrual age of 37 weeks, by which time apnoea of prematurity usually resolves spontaneously.
U kliničkoj praksi, liječenje obično traje sve dok nedonošče ne dosegne gestacijsku dob od 37 tjedana, do koje apneja nedonoščeta obično spontano nestaje.
In clinical practice, treatment will be based on the need to control serum phosphorus levels, though patients who respond to Velphoro therapy usually achieve optimal serum phosphorus levels at doses of 1,500 mg-2,000 mg iron per day (3 to 4 tablets).
U kliničkoj praksi liječenje će se temeljiti na potrebi za kontrolom razine fosfora u serumu, premda bolesnici koji reagiraju na terapiju lijekom Velphoro obično postižu optimalne razine fosfora u serumu pri dozama od 1500 mg – 2000 mg željeza na dan (3 do 4 tablete).
In clinical practice, whole blood trough levels have generally been in the range of 5-20 ng/mL in kidney transplant patients in the early post- transplant period, and 5-15 ng/mL during subsequent maintenance therapy.
U kliničkoj praksi najniže razine u punoj krvi općenito su bile u rasponu od 5-20 ng/mL u bolesnika s transplantiranim bubregom u ranom razdoblju nakon transplantacije i 5-15 ng/mL tijekom naknadne terapije održavanja.
In clinical RA studies and post-marketing experience, rare cases of opportunistic infections have been observed and included fungal, mycobacterial, bacterial, and viral pathogens.
U kliničkim ispitivanjima u bolesnika s RA i postmarketinškom iskustvu primijećene su u rijetkim slučajevima oportunističke infekcije koje su uključivale gljivične, mikobakterijske, bakterijske i virusne patogene.
In clinical registrational studies the incidence of cholecystitis was 0.5%.
U kliničkim ispitivanjima incidencija kolecistitisa bila je 0,5%.
In clinical studies 1468 patients received Plegridy for up to 177 weeks (overall exposure equivalent to 1932 person-years).
U kliničkim ispitivanjima 1468 bolesnika primalo je Plegridy do 177 tjedna (ukupna izloženost jednaka 1932 bolesnik-godina).
In clinical studies 24% of patients treated with MIRCERA were ageg 65 to 74 years, while 20% were ageg 75 years and over.
U kliničkim je ispitivanjima 24% bolesnika koji su primali lijek MIRCERA imalo između 65 i 74 godine, a 20% ih je imalo 75 i više godina.
In clinical studies 36% of infliximab-treated patients were treated for infections compared with 25% of placebo-treated patients.
U kliničkim su se ispitivanjima infekcije pojavile u 36% bolesnika liječenih infliksimabom, u odnosu na s 25% bolesnika koji su dobivali placebo.
In clinical studies 8.0% and 1.8% of patients treated with Gilenya 0.5 mg experienced an asymptomatic elevation in serum levels of ALT of ≥3x ULN (upper limit of normal) and ≥5x ULN, respectively.
U kliničkim ispitivanjima 8,0% odnosno 1,8% bolesnika liječenih Gilenyom 0,5 mg pojavilo se asimptomatsko povišenje razine ALT u serumu od ≥3 x GGN (gornje granice normale), odnosno ≥5 x GGN.
In clinical studies 99.6% to 100% who received Gardasil 9 became seropositive for antibodies against all 9 vaccine types by Month 7 across all groups tested.
U kliničkim ispitivanjima je 99,6% do 100% onih koji su primili Gardasil 9 postalo seropozitivno za protutijela na svih 9 tipova sadržanih u cjepivu do mjeseca u svim testiranim skupinama.
In clinical studies and post-marketing experience cardiac failure has been reported in patients with pramipexole.
U kliničkim ispitivanjima i tijekom razdoblja nakon izdavanja odobrenja za stavljanje gotovog lijeka u promet prijavljeno je zatajenje srca kod bolesnika na pramipeksolu.
In clinical studies and post-marketing experience, rare cases of opportunistic infections have been observed and included fungal, mycobacterial, bacterial, and viral pathogens.
U kliničkim ispitivanjima i postmarketinškom iskustvu primijećene su u rijetkim slučajevima oportunističke infekcije koje su uključivale gljivične, mikobakterijske, bakterijske i virusne patogene.
In clinical studies and post-marketing spontaneous reports, everolimus has been associated with cases of pneumocystis jirovecii (carinii) pneumonia (PJP, PCP), some with fatal outcome (see section 4.4).
U kliničkim ispitivanjima i spontanim prijavama nakon stavljanja lijeka u promet, everolimus je bio povezan sa slučajevima pneumonije koju uzrokuje Pneumocystis jirovecii (carinii) (PJP, PCP), od kojih su neki imali smrtni ishod (vidjeti dio 4.4).
In clinical studies and the post-marketing setting pulmonary adverse effects including interstitial lung disease, pulmonary oedema, and lung infiltration have been reported in some cases with an outcome of respiratory failure or acute respiratory distress syndrome (ARDS), which may be fatal (see section 4.4).
U kliničkim ispitivanjima i nakon stavljanja lijeka u promet, u nekim su slučajevima zabilježene plućne nuspojave uključujući intersticijsku bolest pluća, plućni edem i infiltraciju pluća, s ishodom u obliku respiratornog zatajenja ili akutnog respiratornog distres sindroma (ARDS), koji može imati smrtni ishod (vidjeti dio 4.4).
In clinical studies and the post-marketing setting pulmonary adverse effects including interstitial lung disease, pulmonary oedema, and lung infiltration have been reported in some cases with an outcome of respiratory failure or acute respiratory distress syndrome (ARDS), which may be fatal (see section 4.4).
U kliničkim ispitivanjima i postmarketinškom okruženju prijavljeni su štetni učinci na pluća , uključujući bolest pluća, plućni edem i plućne infiltracije s posljedičnim zatajenjem disanja ili akutnim sindromom respiracijskog distresa (ARDS), koji mogu imati smrtni ishod (vidjeti dio 4.4).
In clinical studies and the post-marketing setting pulmonary adverse effects including interstitial lung disease, pulmonary oedema, and lung infiltration have been reported in some cases with an outcome of respiratory failure or acute respiratory distress syndrome (ARDS), which may be fatal (see section 4.4).
U kliničkim ispitivanjima te nakon stavljanja lijeka u promet prijavljeni su plućni štetni događaji, uključujući intersticijsku bolest pluća, plućni edem i plućnu infiltraciju, u nekim slučajevima s ishodom respiratornog zatajenja ili sindroma akutnog respiratornog distresa (ARDS), koji mogu biti smrtonosni (vidjeti dio 4.4).
In clinical studies comparing PROCYSBI to the immediate-release cysteamine bitartrate, one third of the patients exhibited very common GI disorders (nausea, vomiting, abdominal pain).
U kliničkim ispitivanjima koja uspoređuju PROCYSBI s cisteamin bitartratom s trenutačnim oslobađanjem, jedna trećina ispitanika je imala vrlo česte GI poremećaje (mučnina, povraćanje i bol u trbuhu).
In clinical studies comparing r-hFSH (follitropin alfa) and urinary FSH in ART (see table 1 below) and in ovulation induction, follitropin alfa was more potent than urinary FSH in terms of a lower total dose and a shorter treatment period needed to trigger follicular maturation.
Kliničke studije koje su uspoređivale r-hFSH (folitropin alfa) i urinarni FSH pri medicinski potpomognutoj oplodnji (vidjeti tablicu 1 ispod) i indukciji ovulacije pokazale su da je folitropin alfa učinkovitiji od urinarnog FSH u smislu manje ukupne doze i kraćeg vremena terapije potrebnog za pokretanje sazrijevanja folikula.
In clinical studies concurrent administration of TNF-antagonists and abatacept has been associated with an increased risk of infections including serious infections compared to TNF-antagonists alone, without increased clinical benefit.
U kliničkim ispitivanjima istodobna primjena inhibitora TNFα i abatacepta bila je povezana s povećanim rizikom od razvoja infekcija, uključujući i ozbiljne infekcije, u odnosu na primjenu samo antagonista TNF-a, a pritom nije došlo do povećanja kliničkog učinka.
In clinical studies conducted for more than 2 years with 351 ankylosing spondylitis patients, 6 malignancies were reported in Enbrel-treated patients.
Šest zloćudnih bolesti je zabilježeno u bolesnika liječenih Enbrelom u kliničkim ispitivanjima trajanja dužeg od 2 godine u 351 bolesnika s ankilozantnim spondilitisom.
In clinical studies doses up to 40 mg/kg body weight were used.
U kliničkim su ispitivanjima primjenjivane doze do 40 mg/kg tjelesne težine.
In clinical studies employing planar imaging techniques, Quadramet accumulates with a lesion-to- normal bone ratio of approximately 5 and a lesion-to-soft tissue ratio of approximately 6.
U kliničkim ispitivanjima u kojima su korištene planarne slikovne tehnike, Quadramet se nakupljao približno 5 puta više u kosti s lezijom u odnosu na zdravu kost, i približno 6 puta više u kosti s lezijom u odnosu na meka tkiva.
In clinical Studies I and II with reslizumab 3 mg/kg, decreases in blood eosinophil counts were seen following the first dose and maintained through 52 weeks of treatment with no signs of tachyphylaxis.
U kliničkim ispitivanjima I i II s reslizumabom u dozi od 3 mg/kg, nakon prve doze opažena su sniženja broja eozinofila u krvi koja su se održala tijekom 52 tjedna liječenja bez ikakvih znakova tahifilaksije.
In clinical studies in adults at a dose of 250 micrograms (total 633 patients) the most frequently observed adverse reactions, at least possibly related to Aloxi, were headache (9 %) and constipation (5 %).
U kliničkim ispitivanjima u odraslih s dozom od 250 mikrograma (ukupno 633 bolesnika) najčešće opažene nuspojave, barem moguće povezane s primjenom lijeka Aloxi, bile su glavobolja (9%) i konstipacija. (5%).
In clinical studies in CSU, Xolair was used in conjunction with antihistamines (anti-H1, anti-H2) and leukotriene receptor antagonists (LTRAs).
U kliničkim ispitivanjima KSU-a, Xolair se primjenjivao zajedno s antihistaminicima (anti-H1, anti- H2) i antagonistima leukotrijenskih receptora.
In clinical studies in hypertensive patients, aliskiren had no clinically important effects on total cholesterol, high density lipoprotein cholesterol (HDL-C), fasting triglycerides, fasting glucose or uric acid.
U kliničkim ispitivanjima hipertenzivnih bolesnika aliskiren nije imao klinički značajnih učinaka na ukupni kolesterol, HDL- kolesterol (HDL-C), trigliceride natašte, glukozu natašte ili mokraćnu kiselinu.
In clinical studies in hypertensive patients, Rasilez had no clinically important effects on total cholesterol, high density lipoprotein cholesterol (HDL-C), fasting triglycerides, fasting glucose or uric acid.
U kliničkim ispitivanjima hipertenzivnih bolesnika Rasilez nije imao klinički značajnih učinaka na ukupni kolesterol, HDL-kolesterol (HDL- C), trigliceride natašte, glukozu natašte ili mokraćnu kiselinu.
In clinical studies in individuals who received Hexacima, the most frequently reported reactions include injection-site pain, irritability, crying, and injection-site erythema.
U kliničkim ispitivanjima provedenima na pojedincima koji su cijepljeni cjepivom Hexacima, najčešće prijavljivane reakcije uključuju bol na mjestu injiciranja, razdražljivost, plač i eritem na mjestu injiciranja.
In clinical studies in kidney transplant patients receiving Envarsus, the most frequent adverse reactions (at least in 2% of patients) were tremor, diabetes mellitus, blood creatinine increased, urinary tract infection, hypertension, BK virus infection, renal impairment, diarrhoea, toxicity to various agents, and toxic nephropathy all of which are known to occur in the respective patient population under immunosuppressive treatment.
U kliničkim ispitivanjima bolesnika s presađenim bubregom koji primaju Envarsus najčešće nuspojave (u najmanje 2% bolesnika) bile su tremor, diabetes mellitus, povišena razina kreatinina u krvi, infekcija mokraćnog sustava, hipertenzija, infekcija virusom BK, oštećenje bubrega, proljev, toksičnost na razne lijekove i toksična nefropatija za koje je sve poznato da se pojavljuju u ovoj populaciji bolesnika koji primaju imunosupresivno liječenje.
In clinical studies in Parkinson’s patients, the 6 month-specific rates of peripheral oedema remained at about 4% through the entire observation period up to 36 months.
U kliničkim ispitivanjima u bolesnika s Parkinsonovom bolešću, kroz cijelo razdoblje praćenja u trajanju od 36 mjeseci incidencija pojave perifernog edema u 6-mjesečnim razmacima bila je oko 4%.
In clinical studies in patients treated with pembrolizumab 2 mg/kg every 3 weeks or 10 mg/kg every two or three weeks, 19 (1.7%) of 1,087 evaluable patients tested positive for treatment-emergent antibodies to pembrolizumab.
U kliničkim ispitivanjima u bolesnika liječenih pembrolizumabom u dozi od 2 mg/kg svaka 3 tjedna ili 10 mg/kg svaka 2 ili 3 tjedna, 19 (1,7%) od 1087 bolesnika koji su mogli biti ocijenjeni imalo je pozitivna protutijela na pembrolizumab koja su se razvila tijekom liječenja.
In clinical studies in patients with advanced phase CML receiving SPRYCEL at the recommended dose (n=304), grade 3 or 4 fluid retention was reported in 8% of patients, including grade 3 or 4 pleural and pericardial effusion reported in 7% and 1% of patients, respectively.
U kliničkim ispitivanjima u bolesnika s KML u uznapredovaloj fazi koji su primali SPRYCEL u preporučenoj dozi (n=304), zadržavanje tekućine 3. ili 4. stupnja bilo je prijavljeno u 8% bolesnika, uključujući pleuralni izljev 3. ili 4. stupnja u 7% i perikardijalni izljev 3. ili 4. stupnja u 1% bolesnika.
In clinical studies in patients with HIV, the only undesirable effects that were consistently considered to be related to filgrastim administration were musculoskeletal pain, bone pain and myalgia.
U kliničkim ispitivanjima bolesnika s HIV-om jedine nuspojave koje su dosljedno smatrane povezanim s primjenom filgrastima bile su mišićno-koštana bol, koštana bol i mijalgija.
In clinical studies in patients with HIV, the only undesirable effects that were consistently considered to be related to filgrastim administration were musculoskeletal pain, bone pain and myalgia.
U kliničkim ispitivanjima bolesnika s HIV-om jedini neželjeni učinci koji su dosljedno smatrani povezanim s primjenom filgrastima bili su mišićno-koštana bol, koštana bol i mijalgija.
In clinical studies in patients with HIV, the only undesirable effects that were consistently considered to be related to filgrastim administration were musculoskeletal pain, bone pain and myalgia.
U kliničkim ispitivanjima među bolesnicima s HIV om, jedine nuspojave za koje se dosljedno smatralo da su povezane s liječenjem filgrastimom bile su mišićno-koštana bol, koštana bol i mialgija.
In clinical studies in patients with HIV, the only undesirable effects that were consistently considered to be related to filgrastim administration were musculoskeletal pain, bone pain and myalgia.
U kliničkim ispitivanjima među bolesnicima s HIV-om, jedine nuspojave za koje se dosljedno smatralo da su povezane s liječenjem filgrastimom bile su mišićno-koštana bol, koštana bol i mialgija.
In clinical studies in RA and CAPS patients, transient elevations of liver enzymes have been seen uncommonly.
Cryopyrin-Associated Periodic Syndromes) manje često su zabilježena prolazna povećanja razine jetrenih enzima.
In clinical studies in RA and CAPS patients, transient elevations of liver enzymes have been seen uncommonly.
U kliničkim ispitivanjima provedenim u bolesnika s RA i CAPS-om manje često su zabilježena prolazna povećanja razine jetrenih enzima.
In clinical studies in RA and CAPS patients, transient elevations of liver enzymes have been seen uncommonly.
U kliničkim ispitivanjima u bolesnika s RA i CAPS-om manje često su zabilježena prolazna povećanja razine jetrenih enzima.
In clinical studies in RA patients, thrombocytopenia has been reported in 1.9% of treated patients compared to 0.3% in the placebo group.
U kliničkim ispitivanjima u bolesnika s reumatoidnim artritisom trombocitopenija je prijavljena u 1,9% liječenih bolesnika u usporedbi s 0,3% u skupini koja je primala placebo.
In clinical studies in RA patients, transient elevations of liver enzymes have been seen uncommonly.
U kliničkim ispitivanjima u bolesnika s RA manje često su zabilježena prolazna povećanja razine jetrenih enzima.
In clinical studies in which 2150 patients with superficial skin infections applied Altargo, the most commonly reported adverse reaction was application site irritation, which affected approximately 1% of patients.
U kliničkim ispitivanjima u kojima je 2150 ispitanika s površinskim infekcijama kože primijenilo Altargo, najčešće prijavljena nuspojava koja je zabilježena kod približno 1% ispitanika, bila je iritacija na mjestu primjene.
In clinical studies in which amlodipine was administered in combination with beta blockers to patients with either hypertension or angina, no adverse effects on electrocardiographic parameters were observed.
U kliničkim ispitivanjima u kojima je amlodipin primjenjivan u kombinaciji s beta- blokatorima bolesnicima ili s hipertenzijom ili anginom pektoris, nisu opažene nuspojave vezane uz elektrokardiografske parametre.
In clinical studies in which amlodipine was administered in combination with beta blockers to patients with either hypertension or angina, no adverse effects on electrocardiographic parameters were observed.
U kliničkim ispitivanjima u kojima je amlodipin primjenjivan u kombinaciji s beta- blokatorima u bolesnika ili s hipertenzijom ili anginom, nisu opaženi štetni učinci vezani uz elektrokardiografske parametre.
In clinical studies in which some of the vaccinees received Infanrix hexa concomitantly with Prevenar (PCV7) as a booster (4th) dose of both vaccines, fever  38.0°C was reported in 43.4% of infants receiving Prevenar and Infanrix hexa at the same time as compared to 30.5% of infants receiving the hexavalent vaccine alone.
U kliničkim ispitivanjima u kojima su neki cijepljenici primili Infanrix hexa istodobno s cjepivom Prevenar (PCV7) u svrhu docjepljivanja (4. doza) jednim i drugim cjepivom, vrućica od  38,0°C prijavljena je u 43,4% dojenčadi koja je primila Prevenar i Infanrix hexa istodobno, u usporedbi s 30,5% dojenčadi koja je primila samo šesterovalentno cjepivo.
In clinical studies involving 1680 patients, OPATANOL was administered one to four times daily in both eyes for up to four months as monotherapy or adjunctive therapy to loratadine 10 mg.
U kliničkim istraživanjima koja su obuhvatila oko 1680 bolesnika, OPATANOL se kapao u oba oka jedan do četiri puta na dan do četiri mjeseca, pri čemu se davao ili kao monoterapija ili kao dodatna terapija uz loratadin 10 mg.